Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug751 | Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies Wiki | 1.00 |
| drug3717 | Wellness Wiki | 1.00 |
| drug1476 | High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT) Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life. Early preventive assessments are very difficult to implement due to the complex hormone-deficiency-induced effects on a large variety of organs and systems with estrogen receptors. In fact, only a few types of interventions have the potential to comprehensively improve the various risk factors and complaints of the menopausal transition. In detail, however, not every form of exercise training or every training protocol is effective for exerting positive effects on selected risk factors. In particular, the training concept for addressing musculoskeletal or cardio-metabolic risk factors differ fundamentally. In several studies, we confirmed the effect of different complex training programs on risk factors of different postmenopausal female cohorts with special consideration of osteoporotic aspects. The training programs applied in this context were characterized by the consistent implementation of recognized training principles and an in general exercise intensity-oriented approach. Recent studies confirmed the effectiveness of this proceeding for women with relevant postmenopausal risk factors including low bone strength. However, the crucial issue of the most effective, feasible and easily customizable training protocol for addressing postmenopausal risk factors remains to be answered, taking into account that the majority of exercise programs were realized in an ambulatory group setting. The aim of the study will be to evaluate the effects of an optimized physical training on risk factors and complaints of (early) postmenopausal women with special consideration of the osseous fracture risk. Note (05.06.2020): Of importance, the intervention has to be cancelled due to COVID-19 lockdown in March 2020 after 13 months of intervention.
Description: Bone Mineral Density (BMD) at the lumbar spine region of interest as determined by Dual Energy x-Ray Absorptiometry (DXA)
Measure: BMD Lumbar Spine Time: from baseline to 13 month follow-upDescription: Bone Mineral Density at the total hip region of interest as determined by DXA
Measure: BMD total Hip Time: from baseline to 13 month follow-upDescription: Muscle density at the para-vertebral region as determined by Magnetic Resonance Imaging (MRI)
Measure: Para-vertebral muscle density Time: from baseline to 13 month follow-upDescription: Muscle density at the mid-thigh region as determined by MRI
Measure: Mid-thigh muscle density Time: from baseline to 13 month follow-upDescription: Metabolic Syndrome Z-Score according to the Internationale Diabetes Federation (IDF)
Measure: Metabolic Syndrome Time: from baseline to 13 month follow-upDescription: Visceral body fat as determined by Magnetic Resonance Imaging (MRI)
Measure: Visceral body fat Time: from baseline to 13 month follow-upDescription: Total body fat as determined by whole body DXA
Measure: Total body fat Time: from baseline to 13 month follow-upDescription: Total Lean Body Mass as determined by whole body DXA
Measure: Total Lean Body Mass Time: from baseline to 13 month follow-upDescription: Menopausal complaints as determined by the Menopause Rating Scale (German version. Questionnaire with 11 items; scale from 0 (no complaints/problems) to 4 (very severe complaints/problem)
Measure: Menopausal complaints Time: from baseline to 13 month follow-upDescription: Maximum isokinetic leg extensor strength as determined by an isokinetic leg press
Measure: Maximum leg strength Time: from baseline to 13 month follow-upDescription: Total fat rate as determined by Bio Impedance technique (BIA)
Measure: Total fat rate Time: from baseline to 13 month follow-upDescription: Fat free mass as determined by BIA
Measure: Fat free mass Time: from baseline to 13 month follow-upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports